Why repurposing drugs for MS can’t be rushed

Why repurposing drugs for MS can’t be rushed

UCD’s Aradhika Patnaik is researching a leukaemia drug to be repurposed for relapsing-remitting multiple sclerosis, the most common form of the disease.

First Drug for Nonrelapsing MS Progression on the Horizon

Current therapies for multiple sclerosis (MS) focus on reducing the frequency and severity of relapses after periods of recovery or remission, leaving patients with nonrelapsing secondary progressive multiple sclerosis (SPMS) without effective options to slow the steady neurodegeneration. But the investigational drug tolebrutinib, a Bruton tyrosine kinase inhibitor, could delay these worsening effects, a phase 3 trial suggests.